{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Wang C"],"funding":["National Natural Science Foundation of China","Forskningsrådet om Hälsa, Arbetsliv och Välfärd","Full-time Postdoc Research and Development Foundation of West China Hospital"],"pagination":["1450-1458"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC8575780"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["125(10)"],"pubmed_abstract":["<h4>Background</h4>To assess the risk of cardiovascular mortality among cancer survivors who developed breast cancer as a second malignancy (BCa-2) compared with patients with first primary breast cancer (BCa-1) and the general population.<h4>Methods</h4>Using the Surveillance, Epidemiology, and End Results database, we conducted a population-based cohort study including 1,024,047 BCa-1 and 41,744 BCa-2 patients diagnosed from the age 30 between 1975 and 2016, and the corresponding US female population (994,415,911 person-years; 5,403,551 cardiovascular deaths). Compared with the general population and BCa-1 patients, we calculated incidence rate ratios (IRRs) of cardiovascular deaths among BCa-2 patients using Poisson regression. To adjust for unmeasured confounders, we performed a nested, case-crossover analysis among BCa-2 patients who died from cardiovascular disease.<h4>Results</h4>Although BCa-2 patients had a mildly increased risk of cardiovascular mortality compared with the population (IRR 1.08) and BCa-1 patients (IRR 1.15), the association was pronounced among individuals aged 30-49 years (BCa-2 vs. population: IRR 6.61; BCa-2 vs. BCa-1: IRR 3.03). The risk elevation was greatest within the first month after diagnosis, compared with the population, but comparable with BCa-1 patients. The case-crossover analysis confirmed these results.<h4>Conclusion</h4>Our findings suggest that patients with BCa-2 are at increased risk of cardiovascular mortality."],"journal":["British journal of cancer"],"pubmed_title":["Cardiovascular mortality among cancer survivors who developed breast cancer as a second primary malignancy."],"pmcid":["PMC8575780"],"funding_grant_id":["81872307","2018-00648"],"pubmed_authors":["Wang C","Fang F","Lu D","Hu K","Deng L","Fall K","Luo C","Tamimi RM","Valdimarsdottir UA"],"additional_accession":[]},"is_claimable":false,"name":"Cardiovascular mortality among cancer survivors who developed breast cancer as a second primary malignancy.","description":"<h4>Background</h4>To assess the risk of cardiovascular mortality among cancer survivors who developed breast cancer as a second malignancy (BCa-2) compared with patients with first primary breast cancer (BCa-1) and the general population.<h4>Methods</h4>Using the Surveillance, Epidemiology, and End Results database, we conducted a population-based cohort study including 1,024,047 BCa-1 and 41,744 BCa-2 patients diagnosed from the age 30 between 1975 and 2016, and the corresponding US female population (994,415,911 person-years; 5,403,551 cardiovascular deaths). Compared with the general population and BCa-1 patients, we calculated incidence rate ratios (IRRs) of cardiovascular deaths among BCa-2 patients using Poisson regression. To adjust for unmeasured confounders, we performed a nested, case-crossover analysis among BCa-2 patients who died from cardiovascular disease.<h4>Results</h4>Although BCa-2 patients had a mildly increased risk of cardiovascular mortality compared with the population (IRR 1.08) and BCa-1 patients (IRR 1.15), the association was pronounced among individuals aged 30-49 years (BCa-2 vs. population: IRR 6.61; BCa-2 vs. BCa-1: IRR 3.03). The risk elevation was greatest within the first month after diagnosis, compared with the population, but comparable with BCa-1 patients. The case-crossover analysis confirmed these results.<h4>Conclusion</h4>Our findings suggest that patients with BCa-2 are at increased risk of cardiovascular mortality.","dates":{"release":"2021-01-01T00:00:00Z","publication":"2021 Nov","modification":"2025-04-18T20:58:15.82Z","creation":"2025-02-19T01:57:20.784Z"},"accession":"S-EPMC8575780","cross_references":{"pubmed":["34580431"],"doi":["10.1038/s41416-021-01549-w"]}}